chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt. states after receiving the 2nd Moderna 06/15/2021, starting to experience heart fluttering *Benadryl, trouble breathing, left side number lasting a week *toes continue, Parkinson's worsening, right swells*pain up to the neck. Primary visit 07/15/2021 visit consulted with recommendations for reporting.
Clusters of tiny canker-like sores called enanthem.; develop a rash on the mucus membranes in the back of my mouth and soft palate.; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8734) via an unspecified route of administration in the right arm on 07Apr2021 at 12:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included oral rash and suspected COVID-19 in Mar2020. The patient had no known allergies to medications, food, or other products. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 08Apr2021 at 16:00, the patient experienced a rash on the mucus membranes in the back of mouth and soft palate. In the days that followed it had become worse and was now clusters of tiny canker-like sores called enanthem. The patient had this rash a few times since she had a strange cold in March 2020, which the patient now thought may have been COVID. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. On an unknown date in Oct2020, the patient underwent lab test which included all strep and herpes tests and the results were negative. The clinical outcome of the event a rash on the mucus membranes in the back of mouth and soft palate, clusters of tiny canker-like sores called enanthem was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
dizziness; Nauseous; This spontaneous case was reported by a patient and describes the occurrence of DIZZINESS (dizziness) and NAUSEA (Nauseous) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A22A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer (1st dose), Pfizer (1st booster) and Pfizer (2nd dose). Past adverse reactions to the above products included No adverse event with Pfizer, Pfizer and Pfizer.    On 19-May-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-May-2022, the patient experienced DIZZINESS (dizziness) and NAUSEA (Nauseous). At the time of the report, DIZZINESS (dizziness) and NAUSEA (Nauseous) had not resolved.            No concomitant medication was reported. The allergies (medications, food and other products) included as unknown. It was unknown that the patient had COVID positive test or diagnosis. Medical History relating to mentioned AE and both Acute and Chronic illnesses at the time of vaccination was unknown. Recent change in status such as improvement or worsening was unknown. Other vaccines given within 1 month prior to Moderna COVID-19 vaccine was unknown. The AE did not cause the patient to seek medical care (office visit, Urgent care, ER, hospitalized). It was unknown the patient experienced a similar event n past. The symptoms was worsened.  No treatment medication was reported.
After 4 days woke up with lymph node under throat on left side where injection was on left side.
sore arm; tiny little cough; This is a spontaneous report received from a contactable consumer (patient). A 90-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, batch/lot number and expiration date not provided), via an unspecified route of administration, on an unspecified date (reported "on Friday") (at the age of 90-year-old), at single dose, for COVID-19 immunization. Medical history included she was just getting over COVID-19. Concomitant medications were not reported. The patient experienced sore arm. It was reported the second dose scheduled four weeks after first dose. Patient was 90 and she could not even remember the phone number a while ago. She just got over COVID 1 or 2 months ago. She was still kind of getting over it, didn't get over it right away. She had the first one and it was fine, she had a little sore arm and the usual. Patient asked if she would need to get the 2 shots since she had COVID. Her appointment was for 07May2021. She didn't know if anyone every really gets over COVID. It hangs on for awhile. She wanted to get what she needs, but if she didn't need it she won't get it. The smell, tiny little cough, different things. The outcome of the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This case was reported by a consumer and described the occurrence of adverse reaction in a female subject of unspecified age who was vaccinated with Influenza vaccine (GlaxoSmithKline). A physician or other health care professional has not verified this report. On an unspecified date, years and years ago, the subject received unspecified dose of Influenza vaccine (unknown route and injection site; lot number not provided). At an unspecified time after vaccination with Influenza vaccine , the subject experienced adverse reaction (she not wish to specify when or what kind of reaction). At the time of reporting the outcome of the event was unspecified.
nausea, dizziness, and sinus pressure/pain that have continued 12 days after vaccination.
Suspected vaccination failure; Had the shot. Months later got shingles; Darn.painfull; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, several months after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure, shingles and pain were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine.  Additional details were provided as follows: The reporter had reported for him/herself. The age group was not reported but was captured as an adult as per the vaccine indication. The age at vaccination was not reported. Several months after receiving vaccination, the patient got shingles which was painful. This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization and laboratory confirmation were not provided.
Fever, flushing, redness/swelling at site of injection, severe arm pain but no loss of motor function.
Day 1 flu like symptons Day 2 low grade fever, achy, elevated blood pressure.  At 10 pm chest pain and breathing issues
MINOR FLU LIKE SYMPTOMS; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow up to request batch/lot number. No concomitant medications were reported. On an unspecified date, the subject experienced minor flu like symptoms. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from minor flu like symptoms. This report was non-serious.
Monday 4-5 hrs after, light headec; Tuesday, achy & painful joints, low grade fever; Wednesday, extremely swollen supravervical lymph node and pain in right shoulder,down right arm
Breakthrough case admission after 2 vaccines Moderna 2/12/21 lot# 105MZ0a;  MOderna 3/12/21 lot# 010A21A
Had minor side effects the night of getting the injection (i.e. sore arm, headache) But on the morning of 1/19, a full week later, when waking up and rolling onto that arm, the injection site felt bruised suddenly. (Didn't have any arm soreness after day 2). It was a small solid bump that was slightly swollen, red, and occasionally itchy
Received Afluria vaccine from local pharmacy on Sun Oct 4. Experienced chills, general fatigue, nausea, slight sore throat and reddened eyes overnight Sunday through Monday. I took aspirin Monday AM which alleviated some of the problems though I still have red eyes with some fatigue.
i started to toss and turn , i couldn't sleep all night, my reaches are non stop. i could not move up from my bed today. im able to walk around little better because the Tylenol. ive had fever too the whole day and night.  i couldn't see well , my coordination was off.
Information has been received from a physician concerning a patient with arthritis who on an unspecified date was vaccinated with a dose of Zostavax. It was reported that patient's arthritis condition became worse after vaccination. Unspecified medical attention was sought. A product quality complaint was not involved. Additional information has been requested.
slight arm pain for few hours; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (slight arm pain for few hours) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     Concurrent medical conditions included Spinal stenosis NOS. Concomitant products included LORAZEPAM for Insomnia and Anxiety, ROSUVASTATIN CALCIUM (ROSUVASTATIN [ROSUVASTATIN CALCIUM]) and FAMOTIDINE (PEPCID AC) for an unknown indication.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, the patient experienced PAIN IN EXTREMITY (slight arm pain for few hours). At the time of the report, PAIN IN EXTREMITY (slight arm pain for few hours) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment information was provided   This case was linked to MOD-2021-338621, MOD-2021-338659 (Patient Link).
Chills; Headache; Muscle pain; Joint pain; This is a spontaneous report from a non-contactable consumer, the patient. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the right arm on 05Apr2021 at 07:45 (at the age 51-years-old) as a single dose for COVID-19 immunisation. Medical history included alopecia areata. The patient had no known allergies to medications, food or other products. Concomitant medications included vitamins (CENTRUM SILVER), coffae arabica; phosphatidyl serine (NEURIVA BRAIN PERFORMANCE) and diphenhydramine hydrochloride (ZZZQUIL) all taken from an unknown date for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206), via an unspecified route of administration in the left arm on 15Mar2021 (at the age 51-years-old)  as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 00:00, the patient experienced chills, headache, muscle and joint pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with DAYQUIL and ibuprofen. The clinical outcome of the events of chills, headache, muscle and joint pain was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected
I had the 1st Pfizer Covid 19 vaccine shot on Thursday 4/8/2021 at 6 pm. I started to feel pain radiating up from my left arm (vaccination site) on Friday morning, 11 am. I have had muscle spasms and Malaysia in my shoulders and neck since that date. I saw my general physician yesterday, 04/26/2021. She said it was likely caused by the vaccination and advised me not to get the second  vaccine.
03/21/2021 around 8:00 in the morning, I noticed I felt very fatigue, I felt dizzy, I slept longer than usual. I slept a lot. when I woke up around 6:30PM I felt better. 3 weeks later on April 11,2021, I went out while I was driving I left pain on my left shoulder  the pain continued got more and more intense on Wednesday I called my doctor he said he couldn't find any rational connection to the vaccine. I couldn't sleep it was really bad.
15 minutes after receiving Prevnar vaccine mom noted the baby to be limp and unresponsive; no cyanosis or seizure noted. Baby recovered in one minute with tactile stimulation. Examination of baby in office was WNL.
blisters are appearing on her face; headache; This case was reported by a consumer via call center representative and described the occurrence of headache in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles.   On 6th March 2020, the patient received the 1st dose of Shingrix. On 17th March 2020, 11 days after receiving Shingrix, the patient experienced headache. On 18th March 2020, the patient experienced blister. On an unknown date, the outcome of the headache and blister were unknown.   It was unknown if the reporter considered the headache and blister to be related to Shingrix.  Additional details were received as follows: The patient with a history of shingles reported that she received dose 1 of Shingrix.  The patient reported that she developed a headache on 17th March 2020.  On 8th March 2020, the patient reported the headache continuing but that blisters are appearing on her face where she once had shingles.  A physician has not yet been consulted to verify shingles. The reporter did not consented to follow up.
Big rash at the injection site; Warm to touch at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Big rash at the injection site) and VACCINATION SITE WARMTH (Warm to touch at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (Big rash at the injection site) and VACCINATION SITE WARMTH (Warm to touch at the injection site). At the time of the report, VACCINATION SITE RASH (Big rash at the injection site) and VACCINATION SITE WARMTH (Warm to touch at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient developed a big rash warm to touch at the injection site 8 days post injection. No treatment details were provided.    Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Severe muscle weakness and pain in left forearm, no pain/weakness in upper arm at site of injection. Pt has trouble lifting or doing much with her arm. Pt does not have any pain or weekness in right arm.  Pt reports no swelling, redness or heat in painful arm.  Since it has only been a couple of days since vaccination, and there were no signs of infection I advised pt to wait 2 more days and if there was no improvement at that point to contact her doctor.
This spontaneous report was received from a 79 years-old male patient, reporting on himself. The patient's did not have pertinent medical history. His concurrent conditions included the allergy to horse serum. The concomitant medications were not provided. On an unspecified date in 2009, the patient was vaccinated with a single dose of PNEUMOVAX 23 (Lot #, expiration date, strength and route of administration were not provided), in his left shoulder area, for pneumonia prevention. It was also mentioned by the patient that at some point (dates unspecified), he was also vaccinated with PREVNAR 13. On an unspecified date in approximately March 2017 (reported as "about 5 weeks ago"), the patient developed pneumonia. He sought medical attention by going to the physician and was hospitalized for 2 days. He was given an unspecified treatment for the event and a chest X ray was performed (results not provided). At the reporting time, the patient had already recovered from the pneumonia. The relatedness between the event and the vaccines was not reported. Upon internal review. pneumonia was considered to be medically significant. No product quality complaint (PQC) was involved. Additional information has been requested.
This spontaneous report was received from a physician refers to a 14 year old female patient with immunodeficiency, asthma and migraine headaches. The patient's medical history included hives with amoxicillin and CEFZIL. On 28-MAY-2015, the patient was vaccinated with VAQTA (lot # K014696, 1 ml, intramuscular) and RECOMBIVAX HB (lot# K020336, 1 ml, intramuscular), the patient was given adult dose of vaccines instead of pediatric doses (overdose). Concomitant therapies included XOLAIR. On an unknown date in 2015, post vaccination, the patient experienced headache and possible lethargy. No lab diagnostic studies were performed. Ibuprofen was given as the treatment for the event. The outcome of thee vents was unknown. The causal relationship between the events and suspect therapies was not reported. Additional information has been requested.
RHABDOMYOLYSIS; This spontaneous report received from a physician concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested.  Laboratory data (dates unspecified) included: Creatine kinase (NR: not provided) greater than 500, 000. No concomitant medications were reported. On an unspecified date, the patient experienced rhabdomyolysis, and was hospitalized (date unspecified). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from rhabdomyolysis. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0 20210537566-COVID-19 VACCINE AD26.COV2.S-RHABDOMYOLYSIS. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
high pitched crying/screaming for 3 hrs; hard to console, very irritable, t101; crying stopped p/3 hrs; pt slept 3 hrs & awoke w/o crying or irritability was nl next day;
Arm soreness within first day, lasted maybe first three days  Arm bruising noticeable at site  Pronounced fatigue day 1- current (day 5) Diarrhea pronounced started day 2, worsened day 3-4 GI cramping day 2-5 current  Intestinal pain and cramping day 2-5 current
recurring chest pain the right side of the chest for weeks sharp pain almost like having a heart attack; Fever; headaches; chills; recurring chest pain the right side of the chest for weeks sharp pain almost like having a heart attack; Almost like vaccine raised blood pressure in body; This is a spontaneous report from a contactable consumer (patient). A 37-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in right arm on 01Oct2021 at 11:00 (Batch/Lot Number: FF2588) (at the age of 37-years-old) as dose 2, single for COVID-19 immunisation. The patient has no medical history and no concomitant medications. The patient had no COVID-19 prior to vaccination. The patient was previously administered with first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot: FF2588), administered in the right arm on 10Sep2021 at 09:00 (at the age of 37-years-old) for COVID-19 immunisation. On 02Oct2021 at 06:00, the patient experienced fever, headaches, chills, recurring chest pain the right side of the chest for weeks sharp pain almost like having a heart attack. The chest pain comes and goes. Almost like the vaccine raised blood pressure in body. Chest pain still occurs at time of this report. The patient did not received treatment for the events. The events resulted in physician office visit. The patient had not tested for COVID-19 post vaccination. Outcome of events was not recovered.   Follow-up attempts are completed. No further information is expected.
swollen lymph nodes, pain and swelling in right breast, pain and numbness in right deltoid, pain and numbness going down left and right bilateral extremities with pins and needle prick feeling constantly all day, taking gabapentin 300mg by mouth at bedtime scheduled because the 200 mg was not enough
This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received vaccine from expire vial) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 054C21A and 054C21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypercholesterolemia since 26-Dec-2018 and Hyperlipidemia since 03-Jun-2018. Concomitant products included ATORVASTATIN from 26-Dec-2018 to an unknown date for an unknown indication.   On 27-May-2021 at 8:51 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jun-2021 at 9:02 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received vaccine from expire vial). On 24-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Received vaccine from expire vial) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.
Fever and chills, nausea, headache, pain at injection site, brief chest pain
Information has been received from a nurse concerning patients who were vaccinated with measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) and developed a rash after receiving vaccine. Additional information has been requested.